Review: taking Novolog and Humalog kwikpen together


Summary

Drug interactions are reported among people who take Novolog and Humalog kwikpen together. This review analyzes the effectiveness and drug interactions between Novolog and Humalog kwikpen. It is created by eHealthMe based on reports of 863 people who take the same drugs from FDA and social media, and is updated regularly.

You are not alone

Join a support group for people who take Novolog and Humalog kwikpen >>>

Personalized health information

On eHealthMe you can find out what patients like me (same gender, age) reported their drugs and conditions on FDA and social media since 1977. Our tools are free and anonymous. 86 million people have used us. 300+ peer-reviewed medical journals have referenced our original studies. Start now >>>


Novolog

Novolog has active ingredients of insulin aspart recombinant. It is often used in diabetes. (latest outcomes from Novolog 14,339 users)

Humalog Kwikpen

Humalog kwikpen has active ingredients of insulin lispro recombinant. It is often used in diabetes. (latest outcomes from Humalog kwikpen 93 users)

On Aug, 26, 2016

863 people who take Novolog, Humalog Kwikpen are studied.


Number of reports submitted per year:

Novolog and Humalog kwikpen drug interactions.

Drug effectiveness over time:

Novolog:
  • < 1 month: 0.0% - (0 of 0 people)
  • 1 - 6 months: 0.0% - (0 of 0 people)
  • 6 - 12 months: 0.0% - (0 of 0 people)
  • 1 - 2 years: 0.0% - (0 of 0 people)
  • 2 - 5 years: 100.0% - (1 of 1 people)
  • 5 - 10 years: 0.0% - (0 of 1 people)
  • 10+ years: 0.0% - (0 of 0 people)
  • not specified: 0.0% - (0 of 0 people)
Humalog Kwikpen:
  • < 1 month: 0.0% - (0 of 0 people)
  • 1 - 6 months: 0.0% - (0 of 1 people)
  • 6 - 12 months: 0.0% - (0 of 0 people)
  • 1 - 2 years: 0.0% - (0 of 0 people)
  • 2 - 5 years: 0.0% - (0 of 0 people)
  • 5 - 10 years: 0.0% - (0 of 0 people)
  • 10+ years: 100.0% - (1 of 1 people)
  • not specified: 0.0% - (0 of 0 people)

Drug effectiveness by gender:

Novolog:
  • female: 0.0% - (0 of 0 people)
  • male: 50.0% - (1 of 2 people)
Humalog Kwikpen:
  • female: 0.0% - (0 of 0 people)
  • male: 50.0% - (1 of 2 people)

Drug effectiveness by age:

Novolog:
  • 0-1: 0.0% - (0 of 0 people)
  • 2-9: 0.0% - (0 of 1 people)
  • 10-19: 0.0% - (0 of 0 people)
  • 20-29: 0.0% - (0 of 0 people)
  • 30-39: 0.0% - (0 of 0 people)
  • 40-49: 0.0% - (0 of 0 people)
  • 50-59: 100.0% - (1 of 1 people)
  • 60+: 0.0% - (0 of 0 people)
Humalog Kwikpen:
  • 0-1: 0.0% - (0 of 0 people)
  • 2-9: 0.0% - (0 of 1 people)
  • 10-19: 0.0% - (0 of 0 people)
  • 20-29: 0.0% - (0 of 0 people)
  • 30-39: 0.0% - (0 of 0 people)
  • 40-49: 0.0% - (0 of 0 people)
  • 50-59: 100.0% - (1 of 1 people)
  • 60+: 0.0% - (0 of 0 people)

Most common drug interactions over time *:

< 1 month:
  • abscess
  • blood creatinine increased
  • exostosis
  • international normalised ratio increased
  • localised infection
  • muscular weakness
  • post procedural haemorrhage
  • skin ulcer
  • hypoglycaemia
  • diabetes mellitus inadequate control
1 - 6 months:
  • hypoglycaemia
  • anti-insulin antibody increased
  • diabetes mellitus inadequate control
  • anti-insulin antibody positive
  • hepatic function abnormal
  • insulin resistance
  • injection site erythema
  • hyperglycaemia
  • injection site induration
  • hypersensitivity
6 - 12 months:
  • anti-insulin antibody positive
  • atrial septal defect
  • gastroschisis
  • haemangioma
  • anti-insulin antibody increased
  • hyperglycaemia
  • foetal exposure during pregnancy
  • hypoglycaemia
  • diabetes mellitus inadequate control
  • insulin resistance
1 - 2 years:
  • hypoglycaemia
  • hyperglycaemia
  • anti-insulin antibody positive
  • nausea
  • anti-insulin antibody increased
  • blood creatine phosphokinase increased
  • diabetes mellitus inadequate control
  • diabetic nephropathy
  • diabetic neuropathy
  • foetal exposure during pregnancy
2 - 5 years:
  • hyperglycaemia
  • hypoglycaemia
  • diabetes mellitus inadequate control
  • anti-insulin antibody increased
  • anti-insulin antibody positive
  • blood glucose increased
  • malaise
  • nausea
  • injection site erythema
  • injection site pruritus
5 - 10 years:
  • asthenia
  • blood glucose fluctuation
  • blood glucose increased
  • malaise
  • blood glucose decreased
  • convulsion
  • depressed level of consciousness
  • drug ineffective
  • nausea
  • shock hypoglycaemic
10+ years:
  • amnesia
  • balance disorder
  • brain injury
  • cerebral haemorrhage
  • cerebral thrombosis
  • cerebrovascular accident
  • cognitive disorder
  • depression
  • dilatation ventricular
  • emotional distress
not specified:
  • blood glucose increased
  • blood glucose decreased
  • hypoglycaemia
  • pain
  • nausea
  • anxiety
  • dyspnoea
  • vomiting
  • dizziness
  • weight decreased

Most common drug interactions by gender *:

female:
  • blood glucose increased
  • nausea
  • blood glucose decreased
  • pain
  • dyspnoea
  • anxiety
  • hypoglycaemia
  • dizziness
  • vomiting
  • weight decreased
male:
  • blood glucose increased
  • hypoglycaemia
  • diabetes mellitus inadequate control
  • anti-insulin antibody positive
  • hyperglycaemia
  • pain
  • drug ineffective
  • blood glucose decreased
  • nausea
  • skin ulcer

Most common drug interactions by age *:

0-1:
  • atrial septal defect
  • foetal exposure during pregnancy
  • gastroschisis
  • haemangioma
  • premature baby
  • maternal drugs affecting foetus
2-9:
  • blood glucose increased
  • angioedema
  • angioneurotic oedema
  • bite
  • blood ketone body increased
  • diabetic ketoacidosis
  • flushing
  • gastroenteritis viral
  • injection site reaction
  • penile swelling
10-19:
  • dehydration
  • pain
  • blood glucose increased
  • convulsion
  • hyperglycaemia
  • alanine aminotransferase increased
  • aphasia
  • arthralgia
  • aspartate aminotransferase increased
  • blood alkaline phosphatase increased
20-29:
  • blood glucose increased
  • anti-insulin antibody positive
  • diabetes mellitus inadequate control
  • diabetic ketoacidosis
  • aggression
  • agitation
  • blood glucose fluctuation
  • periodontitis
  • psychomotor hyperactivity
  • tic
30-39:
  • blood glucose increased
  • anti-insulin antibody increased
  • insulin resistance
  • blood glucose decreased
  • injection site pain
  • fall
  • hyperglycaemia
  • pain
  • anger
  • ankle fracture
40-49:
  • blood glucose increased
  • skin ulcer
  • malaise
  • muscular weakness
  • pain
  • asthenia
  • diabetes mellitus inadequate control
  • headache
  • abscess
  • blood creatinine increased
50-59:
  • blood glucose increased
  • hypoglycaemia
  • diabetes mellitus inadequate control
  • hyperglycaemia
  • nausea
  • anxiety
  • dyspnoea
  • dizziness
  • pain
  • drug ineffective
60+:
  • blood glucose increased
  • hypoglycaemia
  • blood glucose decreased
  • renal failure acute
  • nausea
  • weight decreased
  • anxiety
  • hyperglycaemia
  • cardiac failure congestive
  • anti-insulin antibody positive

* Approximation only. Some reports may have incomplete information.

How to use the study: print a copy of the study and bring it to your health teams to ensure drug risks and benefits are fully discussed and understood.

Do you take Novolog and Humalog kwikpen?

Can you answer these questions?

More questions for: Novolog, Humalog kwikpen

You may be interested in these reviews

More reviews for: Novolog, Humalog kwikpen

On eHealthMe, Novolog (insulin aspart recombinant) is often used to treat diabetes. Humalog kwikpen (insulin lispro recombinant) is often used to treat diabetes. Find out below the conditions the drugs are used for and how effective they are.

What is the drug used for and how effecitve is it:


NOTE: The study is based on active ingredients and brand name. Other drugs that have the same active ingredients (e.g. generic drugs) are NOT considered.

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only, and has not been supported by scientific studies or clinical trials unless otherwise stated. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

You may report adverse side effects to the FDA at http://www.fda.gov/medwatch/ or 1-800-FDA-1088 (1-800-332-1088).

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.